PMID: 365127May 1, 1978Paper

Clinical pharmacology of phenelzine

Archives of General Psychiatry
D S RobinsonD Bartlett


There is renewed interest in the clinical pharmacology of phenelzine sulfate and other monoamine oxidase (MAO) inhibitors. Newer clinical and analytic techniques recently have been applied to investigations of this class of drugs in man. The results show that drugs such as phenelzine are effective in nonendogenous depression and phobic disorders. Clinical response to phenelzine is related to platelet MAO inhibition and dosage per unit body weight. High percent MAO inhibition in platelets at two weeks is associated with greater improvement after a six-week course of treatment. Our data show that a safe, effective phenelzine dose in 1 mg/kg body weight per day. These results have delineated the pharmacologic and therapeutic effects of phenelzine and support a continuing role for MAO inhibitors in psychopharmacology.

Related Concepts

Transient Situational Disturbance
Amitriptyline Hydrochloride
Blood Platelets
Clinical Trials
Depressive Symptoms
Dose-Response Relationship, Drug
Double-Blind Method
Monoamine Oxidase

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Related Papers

British Medical Journal
The British Journal of Psychiatry : the Journal of Mental Science
C Q MountjoyI M Leitch
The British Journal of Psychiatry : the Journal of Mental Science
P Tyrer, D Steinberg
© 2021 Meta ULC. All rights reserved